Results 171 to 180 of about 12,392,515 (266)

An Automated Microfluidic System for Haemostasis Assessment in Cirrhosis With Thrombocytopenia

Liver International, Volume 46, Issue 10, October 2026.
ABSTRACT Background & Aims Conventional laboratory tests do not capture platelet–vessel wall interactions (primary haemostasis) occurring in vivo, limiting guidance before invasive procedures. This is relevant in patients with thrombocytopenia, hallmark of advanced cirrhosis. Microfluidic assays may overcome these limitations.
Niccolò Bitto, Giulia Tosetti, Armando Tripodi, Anna Lecchi, Silvia La Marca, Lidia Padovan, Erica Scalambrino, Marigrazia Clerici, Camilla Caputo, Martina Lucà, Massimo Primignani, Anna Ludovica Fracanzani, Pietro Lampertico, Flora Peyvandi, Vincenzo La Mura   +14 more
wiley   +1 more source

Cryoprecipitate utilisation, shortages and institutional policies in the United States: A survey of practices and policies

Transfusion Medicine, Volume 36, Issue 5, Page 503-510, October 2026.
Abstract Background Since the COVID‐19 pandemic, demand for blood products has remained high, while donations have declined. Institutional policies guiding the use of these products may affect their availability, utilisation and waste. We surveyed blood banks (BBs) in the United States (U.S.) to assess policies and practices related to cryoprecipitate ...
Chinelo P. Onyenekwu, Mariam Ratiani, Jenna Wade, Angela Treml   +3 more
wiley   +1 more source

Hemophilia B gene therapy: a NAb-solute barrier overcome by adeno-associated virus serotype 5. [PDF]

Res Pract Thromb Haemost
Kaczmarek R.
europepmc   +1 more source

Response to hemophilia B gene therapy based on adenoassociated virus serotype 5 antibody status. [PDF]

Res Pract Thromb Haemost
Miesbach W, Srivastava A.
europepmc   +1 more source

Marstacimab for People with Severe Hemophilia A or Moderate to Severe Hemophilia B Without Inhibitors: A Plain Language Summary of Publication of the BASIS Study. [PDF]

Ther Adv Hematol
Matino D, Palladino A, Taylor CT, Hwang E, Raje S, Nayak S, McDonald R, Acharya SS, Mahlangu J, Jimenez-Yuste V, Choraria N, Yang R, Li CK, Al-Khabori M, Wali Y, Adrian JM, Park YS, Zülfikar OB, Teeter J.   +18 more
europepmc   +1 more source

Diagnostic challenges and perioperative management of a lateral cystic neck mass in an adult patient with hemophilia B: A case report. [PDF]

SAGE Open Med Case Rep
Ruley WG, Greene WA, Cranfield DA, Vasan NR.   +3 more
europepmc   +1 more source

Etranacogene dezaparvovec in people with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: a 4-year subgroup analysis of the Health Outcomes with Padua Gene; Evaluation in Hemophilia B (HOPE-B) trial. [PDF]

Res Pract Thromb Haemost
Raheja P, O'Connell N, Verhamme P, Kampmann P, Lemons RS, Wang F, Gill S, Monahan PE, Le Quellec S, Leebeek FWG.   +9 more
europepmc   +1 more source

Effect of marstacimab in young people living with severe hemophilia A or moderate to severe hemophilia B without inhibitors: A plain language summary from the BASIS study. [PDF]

Ther Adv Hematol
Patel P.
europepmc   +1 more source

The Template-Jumping Editing Approach in <i>F9</i>-Associated Hemophilia B Gene Therapy. [PDF]

Int J Mol Sci
Sattarov R, Kuznetsov A, Klimko V, Ignatyeva E, Ivanov R, Karabelsky A, Fizikova A.   +6 more
europepmc   +1 more source

Molecular mechanisms and therapeutic strategies for the recurrent F9 (c.520 + 13 A > G) variant in hemophilia B. [PDF]

Hum Genomics
Zhang H, Wang C, Gu M, Meng Z, Guo Y, Zhang W, Balestra D, Guo W, Wang B.   +8 more
europepmc   +1 more source